Abstract
In recent years, the detection of nitrosamine precursors has become an important issue for regulatory authorities such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). The present study provides a pre-column derivatization method for the analysis of dimethylamine (DMA) and diethylamine (DEA) in pharmaceutical products using HPLC and a fluorescence detector. Appropriate chromatographic parameters, including mobile phase composition (organic solvent, buffer, pH), elution type, flow rate, temperature, and λexcitation/emission, were investigated. Analysis was performed at λ(excitation) = 450 nm and λ(emission) = 540 nm on a C(18) column (at 40 °C) using gradient elution as a mobile phase with Eluent A: Phosphoric Acid Buffer (20 mM, pH = 2.8) and Eluent B: methanol, with a flow of 0.8 mL/min. The method was validated according to ICH specifications in terms of linearity (0.5-10 ng/mL for DMA and 5-100 ng/mL for DEA), specificity, and robustness, as well as repeatability, intermediate precision (%RSD < 2.9), and accuracy (% recovery 98.2-102.0%). The derivatization process was optimized using the "Crossed D-Optimal" experimental design procedure, where one mixture component was cross-correlated with two factors. The stability of the samples was studied over a period of one month. To process the samples (pharmaceuticals), various purification techniques were tried using solid/liquid or liquid/liquid extraction with dichloromethane. Finally, a straightforward solid-phase extraction (SPE, C(18)) method was chosen prior to derivatization. The method was successfully applied, since the extraction recoveries were >81.6% for DMA (0.5 ppm) and >81.1% for DEA (5 ppm). Based on the results obtained and the available literature, the scientific community seeks, by proposing flexible analytical methods, to delimit the problem of nitrosamines.